LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
Dateline City: KENILWORTH, N.J. AstraZeneca and Merck’s LYNPARZAImproved Radiographic Progression Free Survival vs. Standard of…